Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	AS605240	2	72	flat	flat	BT549 AS-605240 0 2 72	8	1.961	Inf	0.91	0.0479	0.0	0.91	0.01	0.414	0.201	0.949	Inf	0.914	0.954	0.0	0.914	0.01	0.418	0.197	0.951
Hs 578T	XL147	2		flat	flat	Hs578T pilaralisib 2	8	2.509	Inf	0.976	0.000255	0.0	0.976	0.01	0.435	0.181	0.997	Inf	0.97	1.0	0.0	0.97	0.01	0.432	0.183	0.996
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.0	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.0	0.582	0.01	0.436	0.179	0.625
BT-549	Sirolimus	2	72	flat	flat	BT549 rapamycin 0 2 72	8	1.830	Inf	0.569	0.384	0.0	0.569	0.01	0.517	0.113	0.618	Inf	0.642	0.677	0.0	0.642	0.01	0.465	0.153	0.679
BT-20	KIN001-244	3	72	flat	flat	BT20 KIN001-244 0 3 72	8	2.608	Inf	0.841	0.062	0.0	0.841	0.01	0.489	0.133	0.935	Inf	0.805	0.922	0.0	0.805	0.01	0.475	0.145	0.919
BT-549	Everolimus	3	72	sigmoid	flat	BT549 everolimus 0 3 72	8	1.587	59.5	0.533	0.425	1e-05	0.395	0.1	0.702	0.0264	NA	Inf	0.656	0.685	0.0	0.656	0.01	0.48	0.141	0.685
Hs 578T	Everolimus	3		flat	flat	Hs578T everolimus 3	8	2.848	Inf	0.664	0.299	0.0	0.664	0.01	0.475	0.144	0.702	Inf	0.592	0.631	0.0	0.592	0.01	0.486	0.136	0.632
HCC38	Everolimus	2	72	sigmoid	flat	HCC38 everolimus 0 2 72	8	2.170	8323.0	0.58	0.376	0.000127	0.417	0.1	0.688	0.0303	NA	Inf	0.6	0.637	0.0	0.6	0.01	0.509	0.119	0.637
HCC70	Sirolimus	2	72	flat	flat	HCC70 rapamycin 0 2 72	8	1.762	Inf	0.685	0.257	0.0	0.685	0.01	0.531	0.103	0.741	Inf	0.739	0.785	0.0	0.739	0.01	0.524	0.108	0.783
HCC38	Sirolimus	1	72	flat	flat	HCC38 rapamycin 0 1 72	8	1.723	Inf	0.531	0.429	0.0	0.531	0.01	0.623	0.0538	0.573	Inf	0.631	0.66	0.0	0.631	0.01	0.536	0.0998	0.661
Hs 578T	Alpelisib	2		flat	flat	Hs578T alpelisib 2	8	2.513	Inf	0.668	0.131	0.0	0.668	0.01	0.599	0.0647	0.856	Inf	0.634	0.847	0.0	0.634	0.01	0.541	0.0969	0.833
BT-20	Everolimus	3	72	flat	flat	BT20 everolimus 0 3 72	8	2.422	Inf	0.475	0.456	0.0	0.475	0.01	0.602	0.0632	0.543	Inf	0.478	0.534	0.0	0.478	0.01	0.561	0.0844	0.534
HCC38	Everolimus	1	72	sigmoid	flat	HCC38 everolimus 0 1 72	8	1.703	11.8	0.54	0.428	0.000126	0.341	0.1	0.688	0.0303	NA	Inf	0.641	0.664	0.0	0.641	0.01	0.571	0.0788	0.665
HCC38	Alpelisib	1	72	flat	flat	HCC38 alpelisib 0 1 72	8	1.738	Inf	0.757	0.0835	0.0	0.757	0.01	0.593	0.0674	0.909	Inf	0.798	0.929	0.0	0.798	0.01	0.579	0.0744	0.923
HCC1806	CAL-101	3	72	flat	flat	HCC1806 idelalisib 0 3 72	8	3.147	Inf	1.02	-0.00869	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	CAL-101	1	72	flat	flat	HCC1806 idelalisib 0 1 72	8	2.695	Inf	1.02	-0.0102	0.0	1.02	0.01	-0.593	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.588	1.0	1.02
HCC70	KIN001-244	1	72	flat	flat	HCC70 KIN001-244 0 1 72	8	1.350	Inf	0.889	0.00722	0.0	0.889	0.01	0.616	0.0568	0.988	Inf	0.926	0.995	0.0	0.926	0.01	0.612	0.0584	0.992
HCC70	Everolimus	1	72	flat	flat	HCC70 everolimus 0 1 72	8	1.366	Inf	0.569	0.354	0.0	0.569	0.01	0.623	0.0534	0.643	Inf	0.718	0.766	0.0	0.718	0.01	0.62	0.0547	0.765
HCC1806	Sirolimus	2	72	sigmoid	sigmoid	HCC1806 rapamycin 0 2 72	8	2.881	0.901	0.782	0.182	0.000189	0.714	0.1	0.661	0.0388	NA	149.0	0.717	0.76	0.000153	0.626	0.1	0.634	0.0489	NA
HCC70	Sirolimus	3	72	sigmoid	sigmoid	HCC70 rapamycin 0 3 72	8	2.548	310.0	0.732	0.227	0.000433	0.63	0.1	0.676	0.034	NA	22876.0	0.693	0.736	0.000237	0.58	0.1	0.659	0.0397	NA
HCC38	TGX221	1	72	sigmoid	sigmoid	HCC38 TGX-221 0 1 72	8	1.724	Inf	0.938	0.0116	0.289	0.941	5.0	0.676	0.0342	NA	Inf	0.947	0.99	0.289	0.949	5.0	0.672	0.0354	NA
BT-20	MK2206	1	72	sigmoid	sigmoid	BT20 MK-2206 0 1 72	8	2.089	Inf	0.732	0.102	4.16	0.529	0.345	0.671	0.0357	NA	Inf	0.741	0.898	4.14	0.538	0.337	0.676	0.034	NA
HCC1806	Sirolimus	3	72	sigmoid	sigmoid	HCC1806 rapamycin 0 3 72	8	3.249	0.223	0.805	0.162	0.000183	0.746	0.1	0.663	0.0382	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
HCC1806	Sirolimus	1	72	sigmoid	sigmoid	HCC1806 rapamycin 0 1 72	8	2.796	1.35	0.775	0.187	0.00019	0.706	0.1	0.661	0.039	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)